Provided by Tiger Trade Technology Pte. Ltd.

Theravance Biopharma

16.64
+0.04000.24%
Post-market: 16.41-0.2300-1.38%19:44 EDT
Volume:349.33K
Turnover:5.79M
Market Cap:856.84M
PE:8.08
High:16.81
Open:16.66
Low:16.40
Close:16.60
52wk High:21.03
52wk Low:8.33
Shares:51.49M
Float Shares:21.84M
Volume Ratio:1.02
T/O Rate:1.60%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.06
EPS(LYR):2.06
ROE:44.85%
ROA:-0.54%
PB:2.89
PE(LYR):8.08

Loading ...

Feb 07, 2020

Beneficial Ownership Change

[Amend] Statement of acquisition of beneficial ownership by individuals
Feb 06, 2020

Beneficial Ownership Change

[Amend] Statement of acquisition of beneficial ownership by individuals
Jan 30, 2020

Major Issues Report

Current report, item 5.02
Jan 28, 2020

Beneficial Ownership Change

Statement of acquisition of beneficial ownership by individuals
Jan 13, 2020

Major Issues Report

Current report, items 7.01 and 9.01
Jan 08, 2020

Major Issues Report

Current report, item 8.01
Dec 26, 2019

Major Issues Report

Current report, items 1.01, 8.01, and 9.01
Dec 04, 2019

Major Issues Report

Current report, items 1.01 and 9.01
Nov 08, 2019

Beneficial Ownership Change

[Amend] Statement of acquisition of beneficial ownership by individuals
Nov 08, 2019

Quarterly Report

Quarterly report [Sections 13 or 15(d)]
Nov 05, 2019

Major Issues Report

Current report, items 2.02 and 9.01
Oct 29, 2019

Beneficial Ownership Change

Statement of acquisition of beneficial ownership by individuals
Sep 30, 2019

Major Issues Report

Current report, item 8.01
Sep 09, 2019

Major Issues Report

Current report, items 7.01 and 9.01
Sep 04, 2019

Major Issues Report

Current report, items 7.01 and 9.01
Aug 05, 2019

Quarterly Report

Quarterly report [Sections 13 or 15(d)]
Jul 31, 2019

Major Issues Report

Current report, items 2.02 and 9.01
Jul 03, 2019

Statement Of Changes In Beneficial Ownership

Statement of changes in beneficial ownership of securities
Jun 18, 2019

Major Issues Report

Current report, items 7.01 and 9.01
Jun 14, 2019

Major Issues Report

Current report, items 7.01 and 9.01